R&D Day on AI-Immunology™ March 19, 2024

At our recent Research & Development (R&D) Day, we provided insights into our AI-Immunology™ platform for fast and effective vaccine target discovery, design, and development. Key takeaway messages from the day were:

• The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologies
• AI-Immunology™ outcompetes standard vaccine target discovery approaches and holds the promise of addressing serious unmet needs
• With a unique modular architecture, AI-Immunology™ is scalable and adaptable towards partner needs
• The potential of AI-Immunology™ is validated by established partnerships, including an ongoing vaccine collaboration with MSD

If you want to learn more, we captured the highlights from the R&D Day in a series of videos. Take a look below. 

Watch Christian Kanstrup, CEO, give an overview of Evaxion's unique differentiators and how we intend to utilize these to save and improve patients' lives.

Watch Andreas Holm Mattsson, Chief AI Officer and Founder of Evaxion, provide an introduction to the company's history and the driving force behind the development of our core AI-Immunology™ platform. In this video, you will gain new insights into the scalable modular architecture of AI-Immunology™ and how it has enabled the company to expand to different therapeutic areas.

Watch Michael Schantz Klausen, Scientist and ML Engineer at Evaxion, give a presentation on EvaxMHC - one of the core building blocks of our AI-Immunology™ platform. In his presentation, Michael takes you through the intricacies of peptide-MHC interactions and how EvaxMHC novel deep-learning algorithms achieve best-in-class performance.

Watch Andreas Holm Mattsson, Chief AI Officer and Founder of Evaxion, present the EDEN™ model and its strides towards addressing pressing global needs such as growing antimicrobial resistance. In his presentation, Andreas walks you through the unique feature recognition capabilities of EDEN™ and how these allow for faster and cheaper vaccine discovery.

Watch Michael Schantz Klausen, Scientist and ML Engineer at Evaxion, give a presentation on RAVEN™, a model from the AI-Immunology™ platform trained to design T-cell hotspot vaccines. In his presentation, Michael explores the various applications of RAVEN™ under different vaccine strategies and the advantages it provide for rapid pathogen outbreak response.

Watch Thomas Trolle, Director of Bioinformatics & AI/ML at Evaxion, present the PIONEER™ model and how it has led the parading shift from traditional one-fits-all approaches into tailored cancer vaccines. In his presentation, Thomas explains how PIONEER™ predicts high-quiality neoantigens by unraveling disease mechanisms, and showcases validating data deriving from Evaxion's clinical trials. 

Watch Christian Garde, Scientific Director of Bioinformatics at Evaxion, give a presentation on ObsERV™, a model that exploits a new source of cancer-specific antigens, enabling the development of ERV-based personalized cancer vaccines. In his presentation, Christian elaborates on the evidence supporting the use of this novel antigen source and provides a first glance at Evaxion’s latest personalized cancer vaccine concept leveraging neoantigens and ERVs.

Watch Christian Garde, Scientific Director of Bioinformatics at Evaxion, give a presentation on our responder model, AI-DEEP™. In his presentation, Christian highlights the current need for better guidance in patients' checkpoint inhibitor (CPI) treatment and how Evaxion aims to address this by leveraging AI-Immunology™ existing predicting capabilities.

Watch Jens Kringelum, VP of AI & Innovation at Evaxion, give a presentation on how Evaxion is addressing difficult to treat cancers with AI-Immunology™.